Cargando…
Novel Cruzain Inhibitors for the Treatment of Chagas’ Disease
The protozoan parasite Trypanosoma cruzi, the etiological agent of Chagas’ disease, affects millions of individuals and continues to be an important global health concern. The poor efficacy and unfavorable side effects of current treatments necessitate novel therapeutics. Cruzain, the major cysteine...
Autores principales: | Rogers, Kathleen E, Keränen, Henrik, Durrant, Jacob D, Ratnam, Joseline, Doak, Allison, Arkin, Michelle R, McCammon, J Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503458/ https://www.ncbi.nlm.nih.gov/pubmed/22613098 http://dx.doi.org/10.1111/j.1747-0285.2012.01416.x |
Ejemplares similares
-
Computational Identification of Uncharacterized Cruzain Binding Sites
por: Durrant, Jacob D., et al.
Publicado: (2010) -
Towards the development of novel Trypanosoma brucei RNA editing ligase 1 inhibitors
por: Durrant, Jacob D, et al.
Publicado: (2011) -
Convergent QSAR
Models for the Prediction of Cruzain
Inhibitors
por: Gonçalves, Rafael Bello, et al.
Publicado: (2023) -
Comparing Neural-Network Scoring Functions and the
State of the Art: Applications to Common Library Screening
por: Durrant, Jacob D., et al.
Publicado: (2013) -
Pyrone-Based Inhibitors of Metalloproteinase Types 2 and 3 May Work as Conformation-Selective Inhibitors
por: Durrant, Jacob D, et al.
Publicado: (2011)